Evidence map›Paper›PMID 41388185›Full record

ArticleOphthalmology and therapy2026

Aflibercept 8 mg in Neovascular AMD-A Fast-Drying Anti-VEGF Drug: A Prospective Morpho-Functional Pilot Study.

Michele Rinaldi, Gilda Cennamo, Marina Concilio, Gaetano Corvino, Alessia Riccardo, Raffaele Nubi, Ciro Costagliola

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07074054 (Early Anatomical and Functional Changes With Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07074054 completednot on this map

Early Anatomical and Functional Changes With Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: A Prospective Case Series

TypeobservationalSponsorFederico II UniversityRan2024 to 2025Enrolled40ConditionsPresence of Retinal Fluid, Changes in Macular Pigment Optical Density
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Michele RinaldiEye Clinic, Department of Neurosciences, Reproductive and Odontostomatological Sciences, Federico II University, Via Pansini n 5, 80131, Naples, Italy.
Gilda CennamoEye Clinic, Department of Neurosciences, Reproductive and Odontostomatological Sciences, Federico II University, Via Pansini n 5, 80131, Naples, Italy. xgilda@hotmail.com.
Marina ConcilioEye Clinic, Department of Neurosciences, Reproductive and Odontostomatological Sciences, Federico II University, Via Pansini n 5, 80131, Naples, Italy.
Gaetano CorvinoEye Clinic, Department of Neurosciences, Reproductive and Odontostomatological Sciences, Federico II University, Via Pansini n 5, 80131, Naples, Italy.
Alessia RiccardoEye Clinic, Department of Neurosciences, Reproductive and Odontostomatological Sciences, Federico II University, Via Pansini n 5, 80131, Naples, Italy.
Raffaele NubiEye Clinic, Department of Neurosciences, Reproductive and Odontostomatological Sciences, Federico II University, Via Pansini n 5, 80131, Naples, Italy.
Ciro CostagliolaEye Clinic, Department of Neurosciences, Reproductive and Odontostomatological Sciences, Federico II University, Via Pansini n 5, 80131, Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study investigated early anatomical and functional outcomes in patients with treatment-naïve neovascular age-related macular degeneration (nAMD) treated with 8 mg aflibercept compared to patients treated with the standard dose of 2 mg aflibercept using spectral domain optical coherence tomography (SD-OCT), microperimetry, and macular pigment optical density (MPOD) after loading phase administration.

methodsThis prospective, observational study included 30 eyes of 30 patients (mean age 70 ± 5 years; 15 male, 15 female) recruited between January and June 2025 at the Eye Clinic of the University of Naples "Federico II". Patients were assigned to one of two age- and gender-matched groups receiving intravitreal injections of aflibercept at the dose of 2 mg (group A) or 8 mg (group B). All patients underwent complete ophthalmological examination, SD-OCT, OCT angiography, microperimetry, fixation stability, and measurement of MPOD at baseline, month 2, and month 4.

resultsGroup B showed an improvement in all parameters, compared to group A, in particular: a greater reduction in central macular thickness (CMT) (p = 0.008), an improvement in best-corrected visual acuity (BCVA) (p = 0.012), increased retinal sensitivity (p = 0.015), increased MPOD (p = 0.027), and reduced bivariate contour ellipse area (BCEA) (p = 0.039). Group B showed a faster drying rate during the first 2 months (70 vs. 40 μm/month) and overall at month 4.

conclusionsIntravitreal injections of aflibercept 8 mg resulted in significant short-term anatomical and functional improvement compared to standard dose and thus appear to be an effective option to achieve faster results in nAMD. MPOD can be considered as a potential new biomarker of macular health to study retinal functional response.

trial registrationThe research protocol was registered on ClinicalTrials.gov (NCT07074054).

Indexed as

AfliberceptAMDAnti-VEGFIntravitreal injectionsMicroperimetryMPODSD-OCT

Identifiers

PMID41388185
PMCPMC12901755

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.